Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Increased by Glenmede Trust Co. NA

Glenmede Trust Co. NA raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 487,131 shares of the biopharmaceutical company’s stock after buying an additional 109,283 shares during the period. Glenmede Trust Co. NA’s holdings in Halozyme Therapeutics were worth $27,883,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in shares of Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $49,000. Toth Financial Advisory Corp purchased a new position in Halozyme Therapeutics in the 3rd quarter worth about $57,000. Finally, FSC Wealth Advisors LLC purchased a new position in Halozyme Therapeutics in the 3rd quarter worth about $65,000. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $35,583,199.52. The trade was a 1.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 60,000 shares of company stock worth $3,425,000 over the last 90 days. 2.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HALO has been the subject of several recent analyst reports. Morgan Stanley raised their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Benchmark reiterated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Finally, Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Trading Up 1.4 %

NASDAQ HALO opened at $48.47 on Thursday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The firm’s fifty day simple moving average is $54.00 and its 200-day simple moving average is $53.71. The company has a market capitalization of $6.17 billion, a PE ratio of 16.05, a price-to-earnings-growth ratio of 0.43 and a beta of 1.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.